EB-BH2024 / Essen Biotech - LARVOL DELTA

BAH241: Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). (clinicaltrials.gov) - P1/2 | N=75 | Recruiting | Sponsor: Essen Biotech | Trial completion date: Dec 2025 ➔ Dec 2028 | Trial primary completion date: Feb 2025 ➔ Feb 2027

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

BAH241: Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). (clinicaltrials.gov) - P1/2 | N=75 | Recruiting | Sponsor: Essen Biotech | Not yet recruiting ➔ Recruiting | Initiation date: Nov 2024 ➔ Jul 2024

CAR T-Cell Therapy • Enrollment open • Trial initiation date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD22